دورية أكاديمية
Reperfusion therapy for acute ischemic stroke: where are we in 2023?
| العنوان: | Reperfusion therapy for acute ischemic stroke: where are we in 2023? |
|---|---|
| عنوان ترانسليتريتد: | Terapia de reperfusão para o acidente vascular isquêmico agudo: onde estamos em 2023? |
| المؤلفون: | Martins SCO; Universidade Federal do Rio Grande do Sul, Hospital de Clínicas de Porto Alegre, Porto Alegre RS, Brazil.; Hospital Moinhos de Vento, Porto Alegre RS, Brazil., Pontes-Neto OM; Universidade de São Paulo, Faculdade de Medicina de Ribeirão Preto, Ribeirão Preto SP, Brazil., Pille A; Universidade Federal do Rio Grande do Sul, Hospital de Clínicas de Porto Alegre, Porto Alegre RS, Brazil.; Hospital Moinhos de Vento, Porto Alegre RS, Brazil., Secchi TL; Hospital Moinhos de Vento, Porto Alegre RS, Brazil., Miranda Alves MA; Universidade Federal de São Paulo, Hospital São Paulo, São Paulo SP, Brazil., Rebello LC; Hospital de Base de Brasília, Brasília DF, Brazil., Oliveira-Filho J; Universidade Federal da Bahia, Salvador BA, Brazil., Lange MC; Universidade Federal do Paraná, Hospital de Clínicas, Curitiba PR, Brazil., de Freitas GR; Hospital Quinta D'Or, Rio de Janeiro RJ, Brazil., de Andrade JBC; Universidade Federal de São Paulo, Hospital São Paulo, São Paulo SP, Brazil., Rocha LJA; Hospital Universitário Professor Alberto Antunes, Maceió AL, Brazil., Bezerra DDC; Hospital Pró-Cardíaco, Rio de Janeiro RJ, Brazil., Souza AC; Hospital Moinhos de Vento, Porto Alegre RS, Brazil., Carbonera LA; Hospital Moinhos de Vento, Porto Alegre RS, Brazil., Nogueira RG; University of Pittsburgh, Pittsburgh PA, United States., Silva GS; Universidade Federal de São Paulo, Hospital São Paulo, São Paulo SP, Brazil. |
| المصدر: | Arquivos de neuro-psiquiatria [Arq Neuropsiquiatr] 2023 Dec; Vol. 81 (12), pp. 1030-1039. Date of Electronic Publication: 2023 Dec 29. |
| نوع المنشور: | Review; Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Thieme Country of Publication: Germany NLM ID: 0125444 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1678-4227 (Electronic) Linking ISSN: 0004282X NLM ISO Abbreviation: Arq Neuropsiquiatr Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: 2022- : [Stuttgart] : Thieme Original Publication: São Paulo. |
| مواضيع طبية MeSH: | Ischemic Stroke* , Brain Ischemia* , Stroke*/etiology, Humans ; Thrombectomy/adverse effects ; Thrombolytic Therapy ; Reperfusion ; Treatment Outcome |
| مستخلص: | Over the last three decades, stroke care has undergone significant transformations mainly driven by the introduction of reperfusion therapy and the organization of systems of care. Patients receiving treatment through a well-structured stroke service have a much higher chance of favorable outcomes, thereby decreasing both disability and mortality. In this article, we reviewed the scientific evidence for stroke reperfusion therapy, including thrombolysis and thrombectomy, and its implementation in the public health system in Brazil. Competing Interests: SCOM reports receiving research grant from the Ministry of Health for Resilient Trial and Resilient-Extend, Research grant from Hospital Moinhos de Vento/PROADI SUS for Resilient-Direct TNK, Resilient Extend-IV, TRIDENT and PROMOTE Study. Speaker fees from Boehringer Ingelheim, Bayer, Pfizer, Daiichi Sanchio, Novo Nordisk, Servier, Novartis, Medtronic, Penumbra, Astra Zeneca and RAPID IA. OMPN reports speaker fees from Boehringer Ingelheim, Astra Zeneca, RAPIDIA, Pfizer; Advisory board of Astra Zeneca, Boehringer Ingelheim RAPIDIA, ALLM. AP reports speaker fees from Boehringer Ingelheim. LCR reports speaker fees from Astra Zeneca and Boehringer Ingelheim. GRF reports speaker fees from Bayer and Pfizer. JBCA reports speaker fees from Astra Zeneca. ACS received a restricted grant from Boehringer Ingelheim. LAC reports receiving a restricted grant from the World Stroke Organization outside of this work and consulting and speaker fees from Allm, Astra Zeneca, Boehringer Ingelheim, and ISchemaView. RGN reports consulting fees for advisory roles with Anaconda, Biogen, Cerenovus, Genentech, Philips, Hybernia, Imperative Care, Medtronic, Phenox, Philips, Prolong Pharmaceuticals, Stryker Neurovascular, Shanghai Wallaby, Synchron, and stock options for advisory roles with Astrocyte, Brainomix, Cerebrotech, Ceretrieve, Corindus Vascular Robotics, Vesalio, Viz-AI, RapidPulse and Perfuze. RGN is one of the Principal Investigators of the “Endovascular Therapy for Low NIHSS Ischemic Strokes (ENDOLOW)” trial. RGN is the Principal Investigator of the “Combined Thrombectomy for Distal MediUm Vessel Occlusion StroKe (DUSK)” trial. RGN is an investor in Viz-AI, Perfuze, Cerebrotech, Reist/Q'Apel Medical, Truvic, Vastrax, and Viseon. TLS, MMR, JOF, MCL, LJAR, DCB have no disclosures to declare. (The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution 4.0 International License, permitting copying and reproduction so long as the original work is given appropriate credit (https://creativecommons.org/licenses/by/4.0/).) |
| References: | Lancet. 2023 Nov 11;402(10414):1753-1763. (PMID: 37837989) Arq Neuropsiquiatr. 2012 Nov;70(11):885-93. (PMID: 23175203) N Engl J Med. 2015 Jan 1;372(1):11-20. (PMID: 25517348) N Engl J Med. 2013 Mar 7;368(10):914-23. (PMID: 23394476) N Engl J Med. 2013 Mar 7;368(10):904-13. (PMID: 23387822) Neurology. 2016 Mar 8;86(10):898-904. (PMID: 26850979) Stroke. 1997 Nov;28(11):2119-25. (PMID: 9368551) Lancet. 2012 Jun 23;379(9834):2364-72. (PMID: 22632907) Int J Stroke. 2021 Nov 3;:17474930211055932. (PMID: 34730045) Stroke. 2005 Oct;36(10):2121-5. (PMID: 16151026) N Engl J Med. 2015 Jun 11;372(24):2296-306. (PMID: 25882510) Lancet. 2016 Apr 23;387(10029):1723-31. (PMID: 26898852) Stroke. 2016 Sep;47(9):2409-12. (PMID: 27462117) JAMA Neurol. 2016 Jun 1;73(6):675-83. (PMID: 27088650) JAMA. 1995 Oct 4;274(13):1017-25. (PMID: 7563451) N Engl J Med. 2015 Jun 11;372(24):2285-95. (PMID: 25882376) Lancet. 2023 Sep 16;402(10406):965-974. (PMID: 37640037) N Engl J Med. 2018 Feb 22;378(8):708-718. (PMID: 29364767) Arq Neuropsiquiatr. 2017 Jan;75(1):50-56. (PMID: 28099563) Stroke. 2021 Jan;52(2):491-497. (PMID: 33430634) N Engl J Med. 2022 Oct 13;387(15):1373-1384. (PMID: 36239645) Lancet. 2004 Mar 6;363(9411):768-74. (PMID: 15016487) Int J Stroke. 2013 Oct;8 Suppl A100:106-11. (PMID: 23692595) Stroke. 2020 Jan;51(1):240-246. (PMID: 31847753) Stroke. 2010 Oct;41(10):2254-8. (PMID: 20829513) Int J Stroke. 2016 Aug;11(6):701-16. (PMID: 27462090) Stroke. 2011 Jun;42(6):1775-7. (PMID: 21474810) N Engl J Med. 2018 Aug 16;379(7):611-622. (PMID: 29766770) JAMA. 2016 Sep 27;316(12):1279-88. (PMID: 27673305) N Engl J Med. 2022 Oct 13;387(15):1361-1372. (PMID: 36239644) N Engl J Med. 2015 Mar 12;372(11):1019-30. (PMID: 25671798) Circulation. 2002 Apr 9;105(14):1679-85. (PMID: 11940547) N Engl J Med. 2021 May 20;384(20):1910-1920. (PMID: 34010530) Lancet. 2012 Jun 23;379(9834):2352-63. (PMID: 22632908) N Engl J Med. 2015 Mar 12;372(11):1009-18. (PMID: 25671797) Stroke. 1997 Nov;28(11):2109-18. (PMID: 9368550) N Engl J Med. 1995 Dec 14;333(24):1581-7. (PMID: 7477192) N Engl J Med. 2018 Jan 4;378(1):11-21. (PMID: 29129157) N Engl J Med. 2013 Mar 7;368(10):893-903. (PMID: 23390923) J Am Heart Assoc. 2017 Feb 15;6(2):. (PMID: 28202431) N Engl J Med. 2016 Jun 16;374(24):2313-23. (PMID: 27161018) N Engl J Med. 2008 Sep 25;359(13):1317-29. (PMID: 18815396) Lancet Neurol. 2020 Feb;19(2):115-122. (PMID: 31831388) Lancet Neurol. 2021 Oct;20(10):795-820. (PMID: 34487721) Stroke. 2019 Dec;50(12):e344-e418. (PMID: 31662037) N Engl J Med. 2020 Jun 11;382(24):2316-2326. (PMID: 32521133) |
| فهرسة مساهمة: | Local Abstract: [Publisher, Portuguese] Nas últimas três décadas, o tratamento do AVC sofreu transformações significativas, impulsionadas principalmente pela introdução das terapias de reperfusão e pela organização dos serviços de AVC. Os pacientes que recebem tratamento em um serviço de AVC bem estruturado têm uma probabilidade muito maior de resultados favoráveis, diminuindo assim a incapacidade funcional e a mortalidade. Neste artigo, revisamos as evidências científicas para as terapias de reperfusão do AVC, incluindo trombólise e trombectomia e sua implementação no sistema público de saúde no Brasil. |
| تواريخ الأحداث: | Date Created: 20231229 Date Completed: 20240103 Latest Revision: 20240105 |
| رمز التحديث: | 20240105 |
| مُعرف محوري في PubMed: | PMC10756810 |
| DOI: | 10.1055/s-0043-1777721 |
| PMID: | 38157871 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1678-4227 |
|---|---|
| DOI: | 10.1055/s-0043-1777721 |